Benzinga | Nov 4, 2021 08:52AM EDT

RBC Capital Maintains Outperform on Sarepta Therapeutics, Lowers Price Target to $145

RBC Capital analyst Brian Abrahams maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and lowers the price target from $148 to $145.